| Document |
Document Title |
|
WO/2016/154335A1 |
The present invention concerns compositions and methods for inhibition of abnormal uterine bleeding (AUB), such as that associated with use of long-acting progestin-only contraceptives (LAPCs). An aspect of the invention concerns composi...
|
|
WO/2016/141503A1 |
A stable Apremilast (represented by formula I) crystal form II free of solvates, a preparation method therefor, a pharmaceutical composition and pharmaceutical uses thereof, as well as a mixed crystal of the crystal form II and a crystal...
|
|
WO/2016/142341A1 |
Compositions comprising melatonin or derivatives thereof are provided for topical administration to the vaginal and/or rectal epithelium to protect against vaginal and/or rectal radiation injury due to radiotherapy.
|
|
WO/2016/141331A1 |
The duration of treatment of erectile dysfunction ("ED") with phosphodiesterase inhibitors can be extended by concomitant administrations of compositions comprising ginger, and a compound that produces L-arginine in vivo. Preferred compo...
|
|
WO/2016/140910A2 |
The present invention provides compositions and methods for the treatment of subjects with impaired fertility or at risk for impaired fertility. In certain aspects, the invention relates to increasing the level or activity of anti-Muller...
|
|
WO/2016/135221A1 |
The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian res...
|
|
WO/2016/135495A1 |
This invention relates to use of compounds in female health applications,for example as a contraceptive. In particular the invention relates to the use of compounds targeting tachykinin receptors, in particular neurokinin B receptors (NK...
|
|
WO/2016/136933A1 |
A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as...
|
|
WO/2016/131098A1 |
ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in ...
|
|
WO/2016/134174A1 |
. Novel methods of improving or enhancing psychological, somatic, and sexual conditions in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are described. Novel me...
|
|
WO/2016/131333A1 |
Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a concentration of 2-30 g...
|
|
WO/2016/131784A1 |
The present invention relates to a novel melatonin-based formulation, particularly a topical liquid composition of melatonin (or analog thereof) suitable for use in intrauterine washing performed during medically assisted reproduction (e...
|
|
WO/2016/127956A1 |
Provided are Clostridium butyricum UCN-12 strain, and the composition and use thereof, the preservation number of the strain being CGMCC No. 9652. The use of the fermentation cultures of the strain, of the fermentation broth or bacteria ...
|
|
WO/2016/123650A1 |
Methods and compositions for delaying the onset of menopause and/or slowing the rate of loss of ovarian reserve are disclosed. The methods may involve administering a therapeutically effective amount of beta-cryptoxanthin (bCX) or a phar...
|
|
WO/2016/124564A1 |
The invention relates to n-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazi
n-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (sGC) for the treatment of cardiovascular diseases, such as for e...
|
|
WO/2016/125937A1 |
The present invention relates to: a method for screening for a material, which can be used as a therapeutic agent for preventing or treating female menopausal disorders by inhibiting the expression or activation of PDK2; and a pharmaceut...
|
|
WO/2016/121865A1 |
Provided are: a lactic-acid-bacteria-containing composition having, on the cell surfaces thereof, a polypeptide derived from the E7 protein of human papilloma virus (HPV), wherein the amount of polypeptide derived from the E7 protein of ...
|
|
WO/2016/120617A1 |
The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environ...
|
|
WO/2016/121892A1 |
The present invention pertains to an infertility ameliorating agent compound that is safe and has high activity. This infertility ameliorating agent compound contains, as an active ingredient, one or a plurality of compounds that are con...
|
|
WO/2016/120844A1 |
The energizing mixture, particularly on sexual level, comprises at least a first plant extract obtained from Epimedium sagittatum, at least a second plant extract obtained from Tribulus terrestris and at least a policosanol.
|
|
WO/2016/121963A1 |
The present invention provides an egg production enhancer for egg-laying chickens, quails, or chickens raised for meat, the egg production enhancer being characterized by containing unheated cashew nut shell oil, heat-treated cashew nut ...
|
|
WO/2016/115949A1 |
Medicine or health care product having 20(R)-ginsenoside Rg3, and the use of 20(R)-ginsenoside Rg3 in the preparation of medicines for the alleviation and/or treatment of impotence.
|
|
WO/2016/113734A1 |
The present invention provides methods and compositions for inhibiting ovulation in a female subject, including a subject in need of contraceptives and a subject undergoing fertility treatments. The methods comprise administering to the ...
|
|
WO/2016/114470A1 |
The present invention relates to a pomegranate extract and a composition containing the same, wherein 1.8-3.2 mg of ellagic acid is contained on the basis of per gram unit of the total weight of the pomegranate extract, and thus there is...
|
|
WO/2016/113679A1 |
The present invention relates to the use of lipoic acid, administered vaginally, for the treatment and/or prevention of threatened abortion or preterm birth in pregnant women with cervical shortening.
|
|
WO/2016/112916A1 |
The present invention relates to antagonists or inhibitors, which bind selectively to selected bone factors, RANKL/OPGbp, OPG, Sclerostin, DKK1, cathepsin K and regulate the interaction between these ligands and their testicular correspo...
|
|
WO/2016/111843A1 |
Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferriti...
|
|
WO/2016/111357A1 |
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-
tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...
|
|
WO/2016/105190A1 |
The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rat...
|
|
WO/2016/095650A1 |
Disclosed are an A-type polymorphic substance of yonkenafil hydrochloride, a preparation method therefor, and a composition and use thereof. A powder diffraction pattern of the A-type polymorphic substance of yonkenafil hydrochloride com...
|
|
WO/2016/095778A1 |
A method for treatment and prevention of air pollution-related diseases, especially diseases related to atmospheric PM2.5 in subjects. The method comprises administering an effective amount of a polyunsaturated fatty acid and vitamin E t...
|
|
WO/2016/097013A1 |
The present invention relates to substituted Pyridyl-cycloalkyl- carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a phar...
|
|
WO/2016/100086A1 |
Methods and materials for treating bacterial vaginosis ("BV") are provided. Cervicovaginal secretions ("CVS") from a woman with Lactobacillus crispatus-dominated (>50%) vaginal microbiota is transplanted to women with BV as a method for ...
|
|
WO/2016/093326A1 |
Provided is a medicinal composition for treating and preventing an angiogenic disease, said medicinal composition comprising a cancer antigen peptide.
|
|
WO/2016/090701A1 |
Disclosed is a long-acting ovulation promoting injection. The long-acting ovulation promoting injection comprises a follicle-stimulating hormone fusion protein and a pharmaceutically acceptable carrier. The content of the follicle-stimul...
|
|
WO/2016/084816A1 |
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...
|
|
WO/2016/084070A1 |
A method of treating uterine fibroid in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating the uterin...
|
|
WO/2016/081592A1 |
Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or ...
|
|
WO/2016/074117A1 |
A pharmaceutical composition for treating deficiency of the kidney and a preparation method therefor. The pharmaceutical composition is prepared by using the following raw materials: 30 to 50 parts of cinnamon, 30 to 50 parts of platycla...
|
|
WO/2016/071283A1 |
Provided is a compound for use in medicine for inhibiting tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO), which compound comprises formula (I) wherein X1, X2, and X7, may be the same or different and each is in...
|
|
WO/2016/070815A1 |
Disclosed in the present invention is a class of new type growth hormone releasing hormone-like peptide. The growth hormone releasing hormone-like peptide is in the form of homodimer and has a relatively high releasing activity of pituit...
|
|
WO/2016/029669A9 |
The present invention relates to a photo-hexyl ether compound, and a pharmaceutical composition and usage thereof. Particularly, the present invention relates to 2(4)-(1-hexyloxyethyl)-6,7-dipropionate-1,3,5,8-tetramethyl-
4(2)-vinylporp...
|
|
WO/2016/068208A1 |
Provided are: a medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.
|
|
WO/2016/069578A1 |
The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using...
|
|
WO/2016/067956A1 |
The present invention provides a microneedle device comprising a base plate, microneedles arranged on the base plate, and coating layers respectively formed on the microneedles, wherein each of the coating layers contains recombinant fol...
|
|
WO/2016/066058A1 |
Provided is a topical Chinese medicinal composition for treating mastitis, said Chinese medicinal composition being made of raw powders or extracts of the following Chinese medicinal materials: 15-20 g of Szechuan lovage, 15-30 g of whit...
|
|
WO/2016/063933A1 |
Provided is a heterocyclic compound that has an excellent RBP4 reducing effect and is useful as a preventive or therapeutic drug for diseases or symptoms mediated by a rise in RBP4 or by retinol supplied by RBP4. A compound represented b...
|
|
WO/2016/060539A1 |
The invention relates to strains of Lactobacillus brevis, LbH2, LbH3, LbH5, LbH9 and LbH13, isolated from the juice of Agave salmiana and the method for the isolation thereof, wherein said strains have bile salt hydrolase (SBH) activity ...
|
|
WO/2016/058194A1 |
A traditional Chinese medicine composition for treating menopausal syndrome, and a preparation method for same, the components and parts by weight of the composition being: 95-105 parts Fallopia multiflora, 115-125 parts Fructus ligustri...
|
|
WO/2016/027163A9 |
Systems, compositions, devices, and methods for treating a mammary condition in a mammal using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the mammary condition may be masti...
|
